Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia

NCT ID: NCT01294618

Last Updated: 2019-05-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-03-31
• Study Completion Date: 2013-09-30

Brief Summary

The aim of this study is to demonstrate the safety and the efficacy of a combination of 2 treatments shown to have some efficacy in Chronic Phase Chronic Myelogenous Leukemia (CP CML) separately, but that have never been combined to date, and this combination is expected to substantially increase the molecular response rates.

Conditions

Chronic Myelogenous Leukemia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

nilotinib + pegylated interferon alpha 2a (PEG-IFN).

Group Type: EXPERIMENTAL

Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.

Intervention Type: DRUG

Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.

Interventions

Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.

Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Performans status 0-2
• CP CML diagnosed since less than 3 months without previous Tyrosine Kinase Inhibitor (TKI) or interferon treatment
• Adequate organic functions:

• Total Bilirubin < 1.5xUpper Normal Range (UNR).
• Aspartate Amino Transferase (ASAT) and Alanine Amino Transferase (ALAT) < 2.5xUNR.
• Alkaline phosphatase ≤ 2.5xUNR
• Amylase and lipase ≤ 1.5xUNR.
• Creatininemia < 1.5xUNR.
• Biological blood standards :

• Potassium ≥ Lower Normal Range (LNR)
• Magnesium ≥ LNR.
• Phosphorus ≥ LNR
• Calcium ≥ LNR.
• Negative pregnancy test within the last 7 days for women with childbearing potential.
• Informed consent signed up
• Compliance to tretament ensured,
• Valid social insurance

Exclusion Criteria

Prior TKI or interferon treatment for the CML

• Contra-indication to IFN
• Pregnancy, breast feeding
• Human Immunodeficiency Virus positive, chronic hepatitis B or C.
• Other BCR-ABL transcript than M-bcr
• Cardiopathy defined as:

• Left Ventricular Ejection Fraction (LVEF) < 45%.
• Left bundle branch block
• Ventricular pacemaker.
• Congenital prolonged QT
• Past ventricular or significant auricular tachyarrythmia
• Clinically significant bradycardia (<50 per minute).
• QTc (Fredericia) > 450 ms (average on 3 Elektrokardiogramm (EKG)).
• Myocardial infarction in the last 12 months.
• Unstable angina within the last 12 months.
• Other significant cardiac diseases.
• Other uncontrolled severe disease (such as diabetes melittus etc…)
• Other ongoing malignant disease.
• Past history of congenital or acquired clinically significant bleeding disorder.
• Previous radiotherapy ≥25% of bone marrow.
• Serious surgery within the past 4 weeks
• Investigational treatment within the last 30 days prior to day 1.
• History of non compliance.
• Cytochrome P450 3A4 (CYP3A4) inhibitors that could not be withdrawn or modified (such as erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil).
• Severe gastro-intestinal disorders (such as gastric ulcer, uncontrolled nausea, malabsorption syndrome, small intestine resection, gastric shunt).
• Hepatic, renal or pancreatic chronic disorder unrelated to CML
• Recent history of acute pancreatitis within a year or history of chronic pancreatic disease .
• Any concommittant treatment inducing QT prolongation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hospices Civils de Lyon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Franck Nicolini, Dr

Role: PRINCIPAL_INVESTIGATOR

Hospices Civils de Lyon

Locations

Hospices Civils de Lyon

Lyon, , France

Countries

France

References

Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Ame S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7.

Reference Type: RESULT

PMID: 26687426 (View on PubMed)

Other Identifiers

2009-560

Identifier Type: -

Identifier Source: org_study_id